La Jolla Pharmaceutical Company with ticker code (LJPC) now have 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 20 and 4 calculating the mean target price we have 10.67. Now with the previous closing price of 4.47 this would imply there is a potential upside of 138.7%. The 50 day MA is 4.48 and the 200 day moving average is 4.33. The market cap for the company is $120m. Visit the company website at: http://lajollapharmaceutical.com
The potential market cap would be $286m based on the market concensus.
La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.
